Navigation Links
STAAR Surgical Reports Solid First Quarter Progress

Total Sales Grow 20% Year-Over-Year

U.S. Visian ICL Sales Increase Year-Over-Year

Cost Reduction Efforts Show Continued Results

Company Ends the Quarter with $10.5 Million in Cash

MONROVIA, Calif., May 6 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported good progress during its first quarter ended March 28, 2008.

Recent Highlights

Corporate Highlights

-- Total sales grew 20% year-over-year to $17,960,000

-- Total international sales growth of 37% year-over-year to


-- Cost reduction programs focused on U.S. operations generated results

-- Strong management of cash resources continued: $10,522,000 on hand

as of March 28 versus $10,895,000 as of December 28, 2007

Visian ICL Highlights

-- Global Visian ICL sales increased by 18%

-- International ICL sales growth of 23%

-- Approval from China's SFDA to market the Toric ICL and Hyperopic ICL

-- U.S. Visian ICL sales increased nine percent year-over-year with

even stronger growth to start Q2

-- Introduced new Visian ICL Growth Program(TM)

-- Increased consumer media coverage in key markets

-- Traffic on more than doubled in March and

April compared to 2007

-- Media focus on complications of the LASIK refractive surgery

IOL Highlights

-- Global cataract sales increased by 22%

-- Strategic roadmap developed to rees 6,999 6,363

Total current liabilities 16,074 11,288

Notes payable - long-term, net of

discount 4,225 4,166

Deferred income taxes - long-term 3,071 570

Other long-term liabilities 2,721 1,930

Total liabilities 26,091 17,954

Series A convertible preferred stock 6,756 -

Stockholders' equity - net 29,692 36,225

Total liabilities, convertible

preferred stock and equity $62,539 $54,179

STAAR Surgical Company

Condensed Consolidated Statements of Cash Flows

(in 000's)


Three Months Ended

March 28, March 30,

2008 2007

Cash flows from operating activities:

Net loss $(8,940) $(3,521)

Adjustments to reconcile net loss

to net cash used in operating


Depreciation of property, plant

and equipment 802 466

Amortization of intangibles 250 120

Amortization of discount 59 -

Fair value adjustment of warrant (24) -

Loss on disposal of property and

equipment 75 53

Equity in operations of joint

venture - (12)

Stock-based compensation expense 438 395

Loss on settlement of pre-

existing distribution

arrangement 3,850 -

Other 51 107

Changes in working capital:

Accounts receivable (1,442) (571)

Inventories 1,984 474

Prepaids, deposits and other

current assets (828) (1,166)

Accounts payable 284 13

Other current liabilities 71 916

Net cash used in operating

activities (3,370) (2,726)

Cash flows from investing activities:

Cash acquired in acquisition of

Canon Staar, net of acquisition

costs 2,743 -

Acquisition of property, plant

and equipment (234) (164)

Proceeds from sale of short-term

investments - restricted 33 -

Net change in other assets (1) 2

Net cash provided by (used

in) investing activities 2,541 (162)

Cash flows from financing activities:

Borrowings under notes payable - 4,000

Borrowings under lines of credit 940 -

Repayments of lines of credit (940) (32)

Repayment of capital lease lines

of credit (152) (13)

Proceeds from the exercise of

stock options - 211

Net cash (used in)

provided by financing

activities (152) 4,166

Effect of exchange rate changes on

cash and cash equivalents 608 62

(Decrease) increase in cash and cash

equivalents (373) 1,340

Cash and cash equivalents, at

beginning of the period 10,895 7,758

Cash and cash equivalents, at end of

the period $10,522 $9,098

turn U.S. IOL product line to


-- Obtained New Technology Intraocular Lens (NTIOL) approval from the

Centers for Medicare and Medical Services (CMS) for Afinity

Collamer(R) Aspheric Three-Piece IOL

-- Submitted NTIOL application to CMS for STAAR Collamer Aspheric

Single Piece IOL which can be injected through a 2.2 mm incision

with the recently introduced nanoPOINT(TM) delivery system.

STAAR Japan Highlights

-- Sales for the quarter were $2.8 million which is on track to exceed

$12 million for the year.

-- Business transferred from exclusive distributor to direct

distribution without losing a customer.

-- End user pricing maintained which is the platform for gross margin


-- Costs are under control and on budget.

"During the quarter, we made meaningful progress towards executing our strategy and improving our financial performance," said Barry G. Caldwell, President and CEO of STAAR Surgical. "The first quarter financials include the purchase accounting expenses, which are not recurring expenses and if excluded would show the positive trends of the base business. We have decreased operating expenses in the U.S. and finished the quarter with $10.5 million in cash. The integration of STAAR Japan is well in hand; we generated year-over-year U.S. sales growth for the Visian ICL and have seen the growth momentum increase since ASCRS. At the same time, we continued to drive international sales growth."

Financial Highlights for the First Quarter Ended March 28, 2008

Total product sales were $17,960,000 which is the highest level of quarterly sales in the over 25 year history of the Company. These sales, compared with $14,917,000 reported for the first quarter of 2007, represent a 20% increase. The increase in sales was led by strong international product sales, which grew 37% during the quarter and included $2,811,000 in sales from STAAR Japan. The impact of changes in currency on sales for the quarter was $1,137,000. Total U.S. sales for the first quarter were $4,524,000, down 11% compared with $5,094,000 in the same period last year. U.S. ICL sales were $1,100,000, up 9.3% as compared with $1,007,000 in the comparable period of 2007.

Gross profit margin was 43.2% compared with 48.9% in the first quarter of 2007. The decrease in margin was primarily due to the low margin associated with the step-up of inventory on the books of STAAR Japan in accounting for the acquisition, which impacted cost of sales by approximately $1.5 million during the quarter. Stepped-up inventory was sold during the quarter and the company expects STAAR Japan to realize gross margin that improves the Company's overall gross margin beginning in the second quarter.

General and Administrative Expenses were $4,441,000, which represents a 24% increase over the first quarter of 2007 of $3,583,000. The increase is due to incremental costs of STAAR Japan of $1,437,000 and increased legal expense in the U.S., partially offset by non-recurrence of the expenses of the Domilens investigation in Q1 2007.

Marketing and selling expenses were $6,467,000, which represents a 22% increase over the first quarter of 2007 of $5,302,000. International marketing and selling expenses increased 60% due to incremental costs of STAAR Japan of $875,000, increased marketing and selling costs to drive continued sales growth internationally, and the effect of exchange. U.S. marketing and selling expenses decreased 14% as compared to the first quarter of 2007 due to decreased commissions and promotional activities partially offset by increased salaries of the recently created direct sales force. U.S. marketing and selling expenses decreased 24% compared to the fourth quarter of 2007.

Research and development expenses were $1.7 million which represents a 7% increase compared to the first quarter of 2007. The increase is due to incremental costs of STAAR Japan of $173,000, partially offset by a 5% decrease in spending in the U.S.

Included in selling, general, and administrative expenses for the three months ended March 28, 2008, was a non-cash settlement loss of approximately $3.9 million associated with the Company's acquisition of STAAR Japan. Prior to the acquisition, Canon Marketing Japan, Inc. had an exclusive right to distribute STAAR Japan's products in Japan on terms that were deemed unfavorable to STAAR Japan and to STAAR when compared to the terms of a comparable at-market distribution arrangement. The $3.9 million loss represents the portion of the purchase price allocated under the accounting rules to the settlement of the unfavorable pre-existing distribution arrangement.

Net loss was $8.9 million or $0.30 per common share, compared with $3.5 million or $0.14 per common share in the first quarter of 2007 and $4.3 million or $0.15 per common share in the fourth quarter of 2007. Of the $8.9 million, $6.0 million resulted from the net loss recorded by STAAR Japan for the quarter, which included $3.9 million in settlement costs and $1.5 million in charges to cost of goods that were recorded as a result of the acquisition.

At March 28, 2008, cash and cash equivalents were $10.5 million compared with $10.9 million at December 28, 2007. During the first quarter of 2008, the Company used approximately $3.4 million in cash for operating activities compared with $2.7 million used during each of the first and fourth quarters of 2007. Approximately $2.5 million of the total cash used in operating activities in the first quarter of 2008 was used by STAAR Japan in assuming distribution from Canon Marketing and for payments on inventory purchased from Canon Marketing.

Cash provided by investing activities was approximately $2.5 million for the first quarter of 2008 and consisted of $2.7 million in net cash acquired in the STAAR Japan acquisition partially offset by $234,000 in purchases of property, plant, and equipment. Cash used in financing activities of $152,000 was the result of payments made on lease lines of credit. Exchange rate changes had a $608,000 favorable effect on cash.

U.S. IOL Profitability Strategy

"We have recently developed a new strategic roadmap designed to return the U.S. IOL product line to profitability," added Mr. Caldwell. "The strategy is to rationalize our current IOL product offering by focusing on products that command premium pricing in the market. We have already received NTIOL designation for our Affinity Collamer Aspheric IOL from CMS, which allows for additional reimbursement per lens when provided to a Medicare patient in an ambulatory surgical center. Most recently, we submitted a new NTIOL application for our STAAR Collamer Aspheric Single Piece IOL which can be injected with our new nanoPOINT delivery system through a 2.2 mm incision. Our next steps include pursuing additional NTIOL submissions as well as clear regulatory pathways for the Collamer Toric IOL and the preloaded silicone IOL offerings. This rationalization will allow us to offer four IOL products in the premium pricing segment. As a result, our goal is to achieve profitability for our rationalized IOL product line offering early next year," Mr. Caldwell concluded.

Conference Call

The Company will host a conference call and webcast on Tuesday, May 6, 2008 at 5:00 p.m. Eastern Time to discuss the Company's first quarter and current corporate developments. The dial-in number for the conference call is 866-250-3615 for domestic participants and 303-262-2004 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, both using passcode 11113294#. To access the live webcast of the call, go to STAAR Surgical's website at An archived webcast will also be available at

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. Collamer(R) is the brand name for STAAR's proprietary collagen copolymer lens material. More information is available at

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including any projections of earnings, revenue, sales, cash or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements regarding expectations for success of the ICL, TICL or other products in the U.S., China or other international markets, prospects for returning U.S. IOL product line to profitability, any statements regarding future performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the challenge of fully integrating STAAR Japan into our business and managing our other foreign subsidiaries, the need to realize product development goals to improve profitability of our U.S. IOL product line, our ability to address FDA concerns over the clinical study for the Toric ICL and to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance, the willingness of surgeons and patients to adopt a new product and procedure, the effect of a possible U.S. recession on elective procedures such as refractive surgery, and the potential effect of recent negative publicity about LASIK on the demand for refractive surgery in general in the U.S. STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

CONTACT: Investors Media

EVC Group EVC Group

Douglas Sherk, 415-896-6820 Steve DiMattia 646-201-5445

Matthew Selinger, 415-896-6817

STAAR Surgical Company

Condensed Consolidated Statements of Income

(In 000's except for per share data)


Three Months Ended

March 28, March 30,

2008 2007

Sales $17,960 $14,917

Cost of sales 10,205 7,622

Gross profit 7,755 7,295

General and administrative 4,441 3,583

Marketing and selling 6,467 5,302

Research and development 1,718 1,610

Loss on settlement of pre-existing

distribution arrangement 3,850 -

Total selling, general and

administrative expenses: 16,476 10,495

Operating loss (8,721) (3,200)

Other income (expense), net 39 (52)

Loss before income taxes (8,682) (3,252)

Income tax provision 258 269

Net loss $(8,940) $(3,521)

Basic and diluted loss per share $(0.30) $(0.14)

Weighted average shares outstanding 29,488 25,652

STAAR Surgical Company

Global Sales

(in 000's)


Three Months Ended

March 28, March 30,

Geographic Sales 2008 2007 % Change

United States $4,524 $5,094 -11.2%

Germany 6,440 6,045 6.5%

Japan 2,952 75 N/A

Other 4,044 3,703 9.2%

Total Sales $17,960 $14,917 20.4%

Product Sales


IOLs $7,948 $6,174 28.7%

Other Cataract 5,464 4,850 12.7%

Total Cataract 13,412 11,024 21.7%


ICL/TICL 4,279 3,642 17.5%

Other Refractive 96 78 23.1%

Total Refractive 4,375 3,720 17.6%

Glaucoma 173 173 0.0%

Total Sales $17,960 $14,917 20.4%

STAAR Surgical Company

Condensed Consolidated Balance Sheet

(in 000's)


March 28, December 28,

2008 2007

Cash, cash equivalents, and short-

term investments - restricted $10,639 $11,045

Accounts receivable trade, net 9,229 6,898

Inventories 15,870 12,741

Prepaids, deposits, and other current

assets 2,754 1,610

Total current assets 38,492 32,294

Property, plant, and equipment, net 6,916 5,772

Intangible assets, net 8,544 3,959

Goodwill, net 7,534 7,534

Advance payment for acquisition of

Canon Staar - 4,000

Other assets 1,053 620

Total assets $62,539 $54,179

Accounts payable $8,973 $4,823

Deferred income taxes - current 102 102

Other current liabiliti

SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
2. STAAR Surgical Plans Major Presence at ASCRS
3. STAAR Surgical Reports Fourth Quarter and Year End Results
4. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
5. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
6. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
7. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
8. STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference
9. Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical
10. STAAR Surgical Reports Third Quarter Results
11. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: